Year-end Sale % OFF 
Abstract
The efficacy and safety of intra-arterial (IA) chemotherapy versus intravenous (IV) chemotherapy for malignant gliomas were studied. We searched eight electronic databases to identify relevant randomized controlled trials that compared IA chemotherapy with IV chemotherapy in patients with malignant gliomas. This study was conducted in compliance with the Quality of Reporting of Meta-analysis (QUORUM) guidelines. The quality of data was assessed using the Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) approach. Four eligible randomized controlled trials including 460 patients were retrieved. Comparing IA chemotherapy and IV chemotherapy for malignant gliomas, disease control rate, efficacy rate, 1-year, 2-year, and 3-year overall survival as well as grade 3/4 leukocytopenia, thrombocytopenia, and anemia were not statistically different. In conclusion, IA chemotherapy is not superior to IV chemotherapy in terms of efficacy and overall survival as a treatment for malignant gliomas.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
